SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-10-31 (netnoticias.mx)
EU penalizes Teva for abuse of power, receives historic fine
500 million dollars for protecting patents and violating competition rules
Read more
2024-10-31 (bizportal.co.il)
The European Commission imposed a fine of half a billion euros on Teva for its conduct in the Copaxone market
According to the findings of the European Commission's investigation, Teva acted on several fronts to prevent competition in the copaxone market, even after the original patent expired
Read more
2024-01-19 (thehindubusinessline.com)
Zydus Lifesciences subsidiary signs licensing agreement with Synthon BV
Zydus Worldwide DMCC partners with Synthon BV to manufacture and market Palbociclib tablets in the US.
Read more
2019-07-02 (businesswire.com)
BC Partners to Acquire Synthon International Holding B.V., a Global Market Leader in the Development of Complex Generics
Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached an agreement to acquire a majority stake in Sy
Read more
(aboutpharma.com)
Teva fined 462 million by the European Commission for obstructing a competing drug against multiple sclerosis
Abuse of dominant position: Teva's role in hindering the arrival of the glatiramer acetate generic on the European market recognized
Read more
(tijd.be)
UCB starts case against generic variant Xyzal
(time) - Pharmaceutical group UCB starts a lawsuit against the Dutch company Synthon, a manufacturer of generic medicines. UCB accuses Synthon of infringing its patent on the anti-allergy drug Xyzal. Synthon wants to market a copy of Xyzal and says that UCB's patent is not valid. The Nijmegen company is a relatively unknown but fast grower in the pharmaceutical sector. It describes itself on its website as a company that does not shy away from 'unorthodox solutions' and does 'what not everyone can or dares to do'.
Read more